| Entries |
| Document | Title | Date |
|---|
| 20080200402 | Use Of Fumagillin And The Derivatives Thereof To Increase The Bioavilability Of The Macrocyclic Lactones - The invention relates to the use of fumagillin and the analog derivatives thereof, as inhibitors of cellular transporters, such as ABC transporters, and especially of P-glycoprotein, in order to increase the bioavailability of active ingredients that can be used in the treatment of pathologies such as cancers or parasitic diseases, and especially in order to increase the bioavailability of the macrocyclic lactones. | 08-21-2008 |
| 20080221045 | Hepatic Function-Improving Agent - An object of the present invention is to provide a means for improving hepatic function of mammals including humans to normal condition. The present invention achieves the above object by providing a hepatic function-improving agent comprising α-glucosyl-hesperidin as an effective ingredient. | 09-11-2008 |
| 20080227727 | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors - Disclosed are methods and compositions useful in identifying an E3 ubiquitin ligase inhibitor and modulating cell growth, comprising contacting a cell with an effective amount of an inhibitor of an E3 ubiquitin ligase, and contacting the cell with an effective amount of a topoisomerase inhibitor, wherein the treatment with the E3 ubiquitin ligase inhibitor and topoisomerase inhibitor modulates cell growth in comparison to a cell treated with the topoisomerase inhibitor alone. The present invention further provides methods for identifying and making an E3 ubiquitin ligase inhibitor. | 09-18-2008 |
| 20080227728 | Therapeutic Agent for the Treatment of a Condition Associated with Peripheral Vascular Disease - The present invention comprises the use of oleuropein in the preventive and/or therapeutic treatment of a condition associated to the peripheral vascular disease, particularly to venous insufficiency. | 09-18-2008 |
| 20080227729 | PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH IMMUNOEFFECTOR COMPOUNDS - Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ cyclic AGPs for selectively stimulating immune responses in animals and plants. | 09-18-2008 |
| 20080234209 | DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS - The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition. | 09-25-2008 |
| 20080242622 | Identification of genetic alterations that modulate drug sensitivity in cancer treatments - This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy. | 10-02-2008 |
| 20080255059 | Regulators of the hedgehog pathway, compositions and uses related thereto - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations. | 10-16-2008 |
| 20080269144 | Synthesis of Inhibitors of P90Rsk - The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural SLO1O1-1 product and has provided access to material sufficient for detailed biological evaluation. | 10-30-2008 |
| 20080274987 | Novel alpha glucosidase activator, pulicarside 1 - A new ent-kaurane type diterpene glucoside, pulicarside (1) was isolated from | 11-06-2008 |
| 20080280839 | Anti-Cancer Activity of Androsace Umbellata Merr. Extract and Contained Triterpene Saponin - The present invention relates to an | 11-13-2008 |
| 20080287375 | Selective Glycosidase Inhibitors, Methods of Making Inhibitors, and Uses Thereof - The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and methods of making the animal models for studying diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc, and treatment of such diseases and disorders. The invention also comprises methods of treating such diseases and disorders. The invention also comprises methods of making the compounds, and methods of making selective glycosidase inhibitors. | 11-20-2008 |
| 20080300198 | Olive Compositions and Methods for Treating Inflammatory Conditions - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker. | 12-04-2008 |
| 20080312166 | Reversal core pharmaceutical system and method - A medication delivery system is disclosed to mitigate or reverse the pharmacologic effect of a medication beyond the desired therapeutic window. The system provides sequential delivery of medications including a first agent which induces a physiologic change, a second agent for reversing the physiologic change, and a medication release delaying agent for delaying the release of the second agent so that, upon receipt of the medication delivery system into the body the first agent is released before the second agent so that the physiologic effect of the first agent is mitigated by the second agent. The system can be a pill with the first agent comprising an outer medication and the second agent an inner medication with the medication release delaying agent intermediate the outer medication and the inner medication. In an example, the first agent can comprise a sleep aid and the second agent an arousal agent. | 12-18-2008 |
| 20090029928 | PEELING PROCESS AND COMPOSITION - Process for the treatment of visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing at least one hydroxy acid chosen from α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids, and mixtures thereof, and at least one cationic polymer, leaving the composition in contact with the skin for a period of time sufficient for the composition to act, and optionally, removing the composition by rinsing. Associated compositions. | 01-29-2009 |
| 20090036386 | Heterobifunctional compounds for selectin inhibition - Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise glycomimetics linked to a compound, for example a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids). | 02-05-2009 |
| 20090036387 | NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS - Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma. | 02-05-2009 |
| 20090054356 | 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME - [Objective] The present invention provides a compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity or the like.
| 02-26-2009 |
| 20090075914 | DEUTERIUM-ENRICHED ODIPARCIL - The present application describes deuterium-enriched odiparcil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
| 20090082285 | Adiponectin expression promoter - To prevent or alleviate various pathologies caused by lifestyle-related diseases, etc., the present invention provides a substance having an effect of promoting the expression and elevating the expression level of adiponectin, and applications thereof. An adiponectin expression promoting agent containing, as an active ingredient, at least one cyanidin compound selected from the group consisting of cyanidin and cyanidin glycosides can be applied to pharmaceutical or food compositions for use in applications in which the pharmacological effects of adiponectin are utilized. | 03-26-2009 |
| 20090088393 | METHODS AND FORMULATIONS FOR CONVERTING INTRAVENOUS AND INJECTABLE DRUGS INTO ORAL DOSAGE FORMS - Oral dosage compositions for drugs normally given intravenously such as Paclitaxel, containing a plant sterol to enhance solubility and a small intestine efflux inhibitor to prevent P-glycoprotein from being a barrier to absorption. | 04-02-2009 |
| 20090088394 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT - Methods and compositions are described for the modulation of central nervous system and/or fetal effects of substances. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of drugs and other compounds out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity at blood-brain, blood-CSF and placental-maternal barriers to increase the efflux of drugs and other compounds from physiological compartments, including central nervous system and fetal compartments. | 04-02-2009 |
| 20090093419 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES - The present invention provides glucopyranosyloxypyrazole derivatives represented by the general formula: | 04-09-2009 |
| 20090099103 | COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising an Erb-B and VEGF receptor inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 04-16-2009 |
| 20090099104 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES - Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 04-16-2009 |
| 20090105164 | SUBSTITUTED INDOLE-O-GLUCOSIDES - Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 04-23-2009 |
| 20090105165 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES - This invention relates to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. | 04-23-2009 |
| 20090124562 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent - Provided is a new anti-cancer agent lower in cell toxicity. | 05-14-2009 |
| 20090131340 | USE OF FLAVONOIDS AS IMMUNOMODULATING OR IMMUNO-PROTECTIVE AGENTS IN COSMETIC AND DERMATOLOGICAL PREPARATIONS - A method of treating or prophylactically treating immunosuppression or allergic and inflammatory symptoms of skin caused by UVB radiation which comprises applying to the skin a cosmetic or dermatological composition which comprises one or more flavonoids. | 05-21-2009 |
| 20090137499 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE - The present invention relates to a benzylphenyl glucopyranoside derivative having an excellent inhibitory effect on human SGLT1 and/or SGLT2 activity. There is provided a compound or a pharmacologically acceptable salt thereof represented by the following general formula (I): | 05-28-2009 |
| 20090143317 | Quercetin Glycoside Composition and Method of Preparing the Same - The present invention provides an α-glycosyl isoquercitrin-containing novel composition which has a high in vivo absorbability, and hence exhibits a significant in vivo antioxidative activity. The present invention further provides preparation methods for such a composition. The composition contains a mixture of quercetin glycosides represented by the following formula: | 06-04-2009 |
| 20090143318 | DEGRANULATION INHIBITOR - An object of the invention is to find in nature a compound having a degranulation inhibitory action comparable to that of steroidal or non-steroidal degranulation inhibitors, but without any side effect such as hormone action or gastrointestinal disturbances which are observed in these inhibitors, and there is provided a degranulation inhibitor comprising as an active ingredient an ellagic acid derivative of the formula (I): | 06-04-2009 |
| 20090156513 | JUCARA AND ACAI FRUIT-BASED DIETARY SUPPLEMENTS - The present disclosure relates to stable, palatable, freeze-dried, fruit-based dietary supplements. In one embodiment, the disclosures relates to compositions of Açai fruit and Jucara fruit with high antioxidant capability and cyclooxygenase-inhibitory activity, and their uses. The disclosure further provides for methods of making stable, palatable, freeze-dried, fruit-based dietary supplements from Açai fruit and Jucara fruit. | 06-18-2009 |
| 20090170787 | COSMETIC COMPOSITION CONTAINING HYDROLYSATES OF ICARIIN - The present invention relates to a cosmetic composition containing hydrolysates of icariin, and more particularly, a cosmetic composition containing hydrolysates of icariin including icaritin, icariside I and icariside II. The hydrolysates of icariin is prepared by a method comprising the steps of: (a) obtaining an extract from a plant containing icariin using water or an organic solvent; and (b) hydrolyzing the plant extract with an acid, a base, an enzyme or a microorganism producing the enzyme. The cosmetic composition according to the present invention is employed for anti-oxidant, anti-aging, whitening or anti-wrinkling effects. | 07-02-2009 |
| 20090170788 | NOVEL USE OF 1, 2, 3, 4, 6-PENTA-O-GALLOYL-BETA-D-GLUCOSE - The present invention relates to novel use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. More particularly, the present invention relates to a pharmaceutical composition and cosmetic composition for preventing and treating skin disease, comprising 1,2,3,4,6-penta-O-galloyl-beta-D-glucose represented by formula 1 as an active ingredient. Also, the invention relates to a method for preventing and treating skin disease using 1,2,3,4,6-penta-O-galloyl-beta-D-glucose, and to the use of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. | 07-02-2009 |
| 20090170789 | Antioxidants for preventing and treating diseases caused by oxidative stress - Antioxidant compositions for the treatment and prophylaxis of illnesses associated with oxidative stress and lack of oxygen in the human body, comprising a complex of a metal selected from the group consisting of iron, copper, zinc and manganese with rutin and ascorbic acid and/or dihydroascorbic acid. Methods for synthesizing the antioxidant compositions and granulates, tablets and capsules containing antioxidant compositions are also provided. | 07-02-2009 |
| 20090176718 | Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome - The present invention provides a pharmaceutical composition for the treatment of a disordered metabolism syndrome comprising anthocyanin-rich extracts from berries. The present invention further provides a method for treating a disordered metabolism syndrome utilizing anthocyanin-rich extracts from berries. | 07-09-2009 |
| 20090181905 | CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS - The invention relates to a crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments. | 07-16-2009 |
| 20090192098 | METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent. | 07-30-2009 |
| 20090197821 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF POORLY WATER SOLUBLE DRUGS AND METHODS OF TREATMENT - The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water-soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for prevention and treatment of disease states. In particular, the embodiment of the invention is directed to compositions comprising suspensions of poorly water-soluble compounds, such as antimitotics and antibiotics, in nanoparticulates and methods of prevention and treatment of chronic disease states, such as cancer, by intraperitoneal and intravenous administration of such compositions | 08-06-2009 |
| 20090203632 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE - A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described. | 08-13-2009 |
| 20090203633 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF - The present invention provides pyrazole derivatives represented by the general formula: | 08-13-2009 |
| 20090221517 | Biologically Active Compounds - Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from | 09-03-2009 |
| 20090275525 | USE OF A LACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses. | 11-05-2009 |
| 20090275526 | Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions. | 11-05-2009 |
| 20090275527 | SKIN AGING TREATMENT COMPRISING PAEONIFLORIN - The present invention relates to a skin aging treatment comprising paeoniflorin as an active ingredient. Since paeoniflorin is effective in significantly inhibiting and improving intrinsic skin aging, significantly inhibiting and improving DNA impairment and skin wrinkling caused by UV and improving existing wrinkles, a cosmetic composition and a pharmaceutical composition comprising paeoniflorin may become a very useful skin aging treatments. | 11-05-2009 |
| 20090312276 | Compositions and Methods for Treating Cancer - Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents. | 12-17-2009 |
| 20090325891 | Cartilage regeneration-promoting agent - An object of the present invention is to provide an excellent cartilage regeneration-promoting agent that can promote regeneration of cartilage efficiently and is highly safe, and a medicine and a food that utilizes the cartilage regeneration-promoting agent. Thus, the present invention relates to a cartilage regeneration-promoting agent that includes at least one of hydroxytyrosol and a precursor of hydroxytyrosol, and to a medicine and a food that includes the cartilage regeneration-promoting agent. | 12-31-2009 |
| 20100004187 | COBALT-AMINE BASED METAL COMPLEX AS AN ANTIBACTERIAL COMPOUND - Disclosed herein is a method of: administering to a subject suspected of being infected with a bacterium, a composition of a cobalt (III) compound having the formula CoR | 01-07-2010 |
| 20100004188 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES - This invention relates to to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. | 01-07-2010 |
| 20100016245 | RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF - The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention. | 01-21-2010 |
| 20100016246 | FOOD COMPOSITION FOR FUNCTIONAL FOODS AND NUTRITIONAL SUPPLEMENTS - A food composition for functional foods and nutritional supplements is for preventing, reducing or treating cardiovascular diseases or mild manifestations thereof, obtained from the combination of extracts derived from citrus species, which contain between 25 and 80% by weight of hesperidin; between and 10% by weight of isonaringin; between 0.5 and 1% by weight of eriocitrin; and between 0.1 and 1% by weight of diosmin and the use of the composition in functional foods and nutritional supplements. | 01-21-2010 |
| 20100016247 | USING BUDDING YEAST TO SCREEN FOR INHIBITORS OF AURORA KINASES - Methods of screening for novel Aurora kinase inhibitors in higher organisms are provided using hypomorphic ipl1 mutant yeast cells. Putative Aurora kinase inhibitors identified by present screening methods may be useful in treating individuals having a proliferative disease, such as cancer. Chemical compounds identified by present methods as selectively inhibiting growth of hypomorphic ipl1 mutant yeast cells may be used in compositions. Compositions or compounds identified by such screening methods may be administered to an individual in need thereof. | 01-21-2010 |
| 20100022464 | FUNCTIONAL FOOD COMPOSITION THAT IS RICH IN PHENOLIC COMPOUNDS AND USE OF SAID COMPOSITION - The invention relates to a functional food composition rich in phenolic compounds, obtained from the combination of citric and olive species extracts, comprising: between 5 and 25% of oleuropein; between 0.1 and 1% of verbascoside, between 0.1 and 1% of hydroxytyrosol, between 1 and 5% of neohesperidin; between 1 and 10% by weight of naringin; between 0.5 and 5% of naringenin and between 0.1 and 2% of apigenin, and its use in food products and supplements. | 01-28-2010 |
| 20100029578 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds - The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF). | 02-04-2010 |
| 20100041617 | Modulating mxa expression - The invention provides compositions and methods for inhibiting cell motility, metastatic cancer and viral infections in a mammal that involve increasing the activity or expression of MxA. | 02-18-2010 |
| 20100069313 | NOVEL POWDERS BASED ON VEGETATION WATER FROM OLIVE OIL PRODUCTION - The present invention is directed a process for the manufacture of a powder comprising vegetation water rich in water-soluble polyphenols, especially rich in hydroxytyrosol, as well as to the powders themselves and dietary supplements, especially in form of tablets, food, feed and cosmetic preparations containing such powders. The process comprises the following steps: A) providing vegetation water (concentrate) containing water-soluble polyphenols; B) (optionally) modifying the water content of the vegetation water (concentrate); C) optionally centrifuging the vegetation water (concentrate) and separating the water-soluble part; D) spray-drying or granulating the (water-soluble part of the) vegetation water (concentrate), preferably in presence of an adjuvant; E) optionally washing the thus obtained powder comprising vegetation water rich in water-soluble polyphenols with an organic solvent. | 03-18-2010 |
| 20100075912 | NOVEL MORPHINE DERIVATIVES - The present invention relates to new morphine-6-glucuronide derivatives, to pharmaceutical compositions thereof and uses thereof. | 03-25-2010 |
| 20100099633 | METHOD FOR ENHANCING NUTRIENT ABSORPTION WITH ASTRAGALOSIDES - The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound. | 04-22-2010 |
| 20100105630 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS - Novobiocin analogues and pharmaceutical composition containing such compounds useful for the treatment and/or prevention of neurodegenerative disorders and autoimmune disorders. | 04-29-2010 |
| 20100113372 | Method For Preparing Kaempferol-3-0-Rutinoside and Composition of Skin External Application Comprising Thereof - Disclosed is a method for the preparation of kaempferol-3-O-rutinoside and a composition of a skin external application comprising kaempferol-3-O-rutinoside as an active ingredient. The method for isolating kaempferol-3-O-rutinoside through hydrolysis uses an enzyme or microbe that removes the sugar selectively from kaempferol-3-O-rutinoside glycosides in a plant extract. Disclosed also is a composition of a skin external application comprising kaempferol-3-O-rutinoside that prevents skin wrinkle. | 05-06-2010 |
| 20100113373 | ANTIVIRAL SUPPLEMENT FORMULATIONS - The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure. | 05-06-2010 |
| 20100113374 | METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of | 05-06-2010 |
| 20100113375 | METHODS AND RELATED COMPOSITIONS USING SPECIFIC FLAVONOIDS AND INDANES TO REDUCE WEIGHT AND INHIBIT LIPASE, ALPHA-AMYLASE AND ALPHA-GLUCOSIDASE ACTIVITY IN MAMMALS - The present invention relates generally to methods and related compositions using flavonoids and/or indanes extracted from the stems and leaves of | 05-06-2010 |
| 20100120705 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 05-13-2010 |
| 20100144658 | NOVEL ANTIBIOTICS, BISPOLIDES A1, A2, AND A3 AS WELL AS BISPOLIDES B1, B2A, B2B AND B3 AND PROCESSES FOR PRODUCING SAID ANTIBIOTICS - Seven novel antibiotic substances could be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as | 06-10-2010 |
| 20100160244 | METHODS AND COMPOSITIONS FOR ENHANCING COLLAGEN, PROTEOGLYCAN, AND GLUTATHIONE SYNTHESIS IN THE SKIN - A composition for application to the skin can stimulate the in vivo synthesis of collagen and proteoglycans and improve the appearance of the skin, increasing its elasticity and fullness. In general, a composition according to the present invention comprises: (1) an antioxidant compound in a quantity sufficient to enhance collagen synthesis in the skin; (2) an organic penetrant in which the antioxidant compound is soluble in a sufficient quantity that a concentration of the antioxidant compound sufficient to enhance collagen synthesis can be applied topically and penetrate the skin; (3) a mixture of essential amino acids or hydrolyzed whey protein; (4) a supplemental source of sulfur; and (5) a topical pharmaceutically acceptable carrier. The antioxidant compound can be lipoic acid or a lipoic acid analogue or derivative. The organic penetrant is preferably benzyl alcohol. Other ingredients, such as esters of tocopherol and ascorbic acid, can be included. | 06-24-2010 |
| 20100160245 | Quercetin-Containing Compositions - This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders. | 06-24-2010 |
| 20100184712 | HYPERBRANCHED POLYMERS BASED ON CYCLODEXTRINS AND POLY (AMIDOAMINES) FOR THE CONTROLLED RELEASE OF INSOLUBLE DRUGS - Hyperbranched, water-soluble polymers, obtainable by Michael polyaddition of α-, β-, or γ-cyclodextrins and amines to bisacrylamides. | 07-22-2010 |
| 20100190733 | Methods of Treating Muscular Dystrophies - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group. | 07-29-2010 |
| 20100197618 | EXTRACT OF REHMANNIA GLUTINASA LIBOSCH FOR REDUCING BLOOD SUGAR, REDUCING BLOOD FAT, TREATING LEUKEMIA, AND PREPARATION METHOD USES THEREOF - The present invention relates to a | 08-05-2010 |
| 20100197619 | CYCLIN-DEPENDENT PROTEIN KINASES INHIBITORS OF SCUTELLARIA FLAVONOID ORGANIC AMINE DERIVATIVES, SYNTHESIS AND USE THEREOF - The present invention provides a series of cyclin-dependent protein kinases (Cdks) inhibitors, | 08-05-2010 |
| 20100210573 | COMPOUND AND COMPOSITIONS FOR TREATMENT OF DISEASE - The present invention relates to flavonoids and to flavonoid-containing compositions for use in the treatment of parasites. | 08-19-2010 |
| 20100216728 | NEW USE OF SPECIFIC CYKLOLIGNANS - The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9′ have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin. | 08-26-2010 |
| 20100216729 | Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts - A group of phytochemical compounds extracted from whole germinated or not germinated black beans ( | 08-26-2010 |
| 20100222287 | Therapeutic Cancer Treatments - Provided are methods for treating prostate cancer by administering a therapeutically effective amount of a hedgehog inhibitor. | 09-02-2010 |
| 20100227826 | Stable Flavonoid Solutions - A stable flavonoid solution comprising (i) at least one flavonoid or flavonoid derivative selected from the group consisting of luteolin, myricetin, baicalin, baicalein, silymarin and kushenol, (ii) a mixture of alkyl glycols of two to seven carbon atoms, (iii) a polyol ether and (iv) an antioxidant. | 09-09-2010 |
| 20100227827 | METHOD OF INCREASING TRYPTOPHAN AND NICOTINAMIDE LEVELS IN VIVO - Novel methods of increasing the biosynthesis of aromatic amino acids and compositions containing the precursors of said aromatic amino acids or nicotinamide and methods of use thereof. In addition, methods of monitoring the therapeutic effects of an anti-oxidant therapy by measuring serum protein thiols as a surrogate or predictor of such therapy are disclosed. | 09-09-2010 |
| 20100227828 | NEW SYNERGISTIC PHYTOCHEMICAL COMPOSITION FOR THE TREATMENT OF OBESITY - Synergistic anti-adipogenic and pro-lipolytic compositions for the prevention and amelioration of adipogenesis and lipolysis mediated diseases, comprising at least two extracts selected from enriched demethylated curcuminoids obtained from | 09-09-2010 |
| 20100234310 | ESTROGENIC COMPOUNDS AND THEIR METHODS OF USE - Isolated compounds and combinations of isolated compounds isolated from | 09-16-2010 |
| 20100234311 | Methicillin-Resistant Staphylococcus Aureus Active Metabolites - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from | 09-16-2010 |
| 20100240603 | EXPRESSION INHIBITOR OF NUCLEAR TRANSCRIPTION FACTOR AP-1 AND PHARMACEUTICALS AND PRODUCTS USING THE SAME - An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present invention is characterized by containing chamaemeloside. In the present invention, chamaemeloside may be contained as an extract of Roman chamomile or German chamomile. The chamaemeloside is contained in Roman chamomile or German chamomile. Conventionally, Roman chamomile and German chamomile have been used as cosmetic materials and herb teas and have no problems in safety. An extract of Roman chamomile or German chamomile and chamaemeloside inhibit the expression of the AP-1 at the gene level (see FIG. | 09-23-2010 |
| 20100261663 | Compositions Containing Harpagoside and Paeoniflorin and Methods for Treatment of Conditions Associated with Pain, Inflammation, Arthritis and Symptoms Thereof - The present invention is directed to compositions incorporating purified herbal ingredients for the treatment of conditions such as pain, inflammation, arthritic conditions and other chronic rheumatic diseases, muscle spasms, and headache, as well as methods for their use. The compositions incorporating purified herbal ingredients can incorporate the following combinations of ingredients: (1) harpagoside and paeoniflorin; (2) harpagoside, paeoniflorin, and bioperin; (3) harpagoside and bioperin; and (4) paeoniflorin and bioperin. | 10-14-2010 |
| 20100261664 | Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof - Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | 10-14-2010 |
| 20100267653 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY - The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections. | 10-21-2010 |
| 20100273726 | METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES ISOLATED FROM LAURUS NOBILIS AND COMBINATIONS THEREOF - This present provides kaempferol-3-(2-E,3-Z-di-p-coumaroyl)-rhamnoside, kaempferol-3-(2-Z-3-E-di-p-coumaroyl)-rhamnoside, and kaempferol-3-(2,3-di-Z-p-coumaroyl)-rhamnoside compounds useful as a new class of anti-bacterial agents. These compounds are extracted from | 10-28-2010 |
| 20100273727 | ORAL ADMINISTRATION COMPOSITION - A composition which has high safety and is excellent in the effect of reducing body fat, such as visceral fat, subcutaneous fat and the like, and neutral fat, and a food, a pharmaceutical and a feed comprising the same, are provided. | 10-28-2010 |
| 20100279961 | PHARMACEUTICAL COMPOSITION HAVING A TRIHYDROXY-CHROMENONE DERIVATIVE - The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate. | 11-04-2010 |
| 20100279962 | MONOSEBACATE OF PYRAZOLE DERIVATIVE - The present invention provides a novel form of 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide with improved storage stability. Since bis[3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide] monosebacate has extremely excellent storage stability, it is useful as a drug substance. Furthermore, it shows an extremely good crystalline property and can be purified by a convenient method, and therefore is suitable for the industrial preparation. | 11-04-2010 |
| 20100286075 | AMPHIPHILIC BLOCK COPOLYMER MICELLE COMPOSITION CONTAINING TAXANE AND MANUFACTURING PROCESS OF THE SAME - A taxane-containing amphiphilic block copolymer micelle composition, including taxane, an amphiphilic block copolymer containing a hydrophilic block and a hydrophobic block, and an osmolality adjusting agent, is described. Also described are a method for preparing the same composition. The composition has excellent stability so that it can prevent rapid release of a drug and can improve a desired pharmacological effect. Additionally, the method enables highly efficient preparation of the composition. | 11-11-2010 |
| 20100292177 | Methods of treatment using combination therapy - Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof. | 11-18-2010 |
| 20100292178 | Method of treating non-insulin dependent diabetes mellitus and related complications - A method of restoring insulin beta cells in a living object to lower a plasma sugar level comprising the step of providing a composition of berberine and catalpol as the two major active ingredients of said composition. The composition is preferably include oleanolic acid and taurine as active ingredients. The composition is pre-made into a single dosage unit. The single dosage contains active ingredients within a range between 1 to 300 mg/kg/dl for a single intake and is in a form of packet powders, solution in vials, ampoules or pre-filled syringes, capsule, tablet, draught in water, syrup and/or cachets. The berberine is obtained from natural herbs | 11-18-2010 |
| 20100305053 | USE OF HESPERIDIN OR OF A DERIVATIVE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF SLACKENED SKIN - The present invention relates to the oral use of an effective amount of hesperidin or of a derivative thereof as a skin finning agent. | 12-02-2010 |
| 20100311675 | NOVEL METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS - The present invention relates to a method for preparing a concentrated extract of | 12-09-2010 |
| 20100311676 | COMPOSITIONS CONTAINING SESAMIN-CLASS COMPOUND(S) AND QUERCETIN GLYCOSIDE(S) - The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced. | 12-09-2010 |
| 20100317605 | THE USE OF EPIMEDIUM FLAVONES AND EFFECTIVE COMPONENTS THEREOF FOR THE PREPARATION OF MEDICAMENTS OF PROMOTING PROLIFERATIONS AND DIFFERENTIATIONS OF NERVE CELLS - The use of epimedium flavones and/or icariins for the preparation of medicaments of promoting proliferations and/or differentiations of nerve cells, is disclosed. | 12-16-2010 |
| 20100323977 | Mucoadhesive nanoparticles for cancer treatment - The present invention relates to a pharmaceutical composition which includes nanoparticles. The nanoparticles include a glyceryl monooleate or monolinoleate (or other mono fatty acid ester); a chitosan; and a cancer therapeutic agent, such as gemcitabine, taxanes, and hydrophobic cancer therapeutic agents). Also disclosed are methods for preparing such nanoparticles and pharmaceutical compositions, as well as methods for treating breast, pancreatic, colon, prostate, and other cancers by parenterally, intravenously, or otherwise administering such nanoparticles and pharmaceutical compositions. | 12-23-2010 |
| 20100331271 | Use of Acacetin and Related Compounds as Potassium Channel Inhibitors - This invention provides a method for treating or preventing human atrial arrhythmia (fibrillation) using the leading flavone compound acacetin, and its derivatives and analogues that inhibit the ultra-rapidly-activating delayed rectifier potassium current (I | 12-30-2010 |
| 20110003761 | BIOLOGICALLY ACTIVE EXTRACT FROM DENDROBIUM PLANT, USE THEREOF AND PROCESS FOR PREPARING THE SAME - A substance having the following formula is provided. | 01-06-2011 |
| 20110003762 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN RELATED DISEASES AND HYPERCHOLESTEROLEMIA - A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient. | 01-06-2011 |
| 20110028415 | USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN LEUKENIA MANAGEMENT - The present invention relates to the use of a compound of formula (I) wherein R | 02-03-2011 |
| 20110028416 | NUTRITIONAL COMPOSITIONS FOR PROMOTION OF BONE GROWTH AND MAINTENANCE OF BONE HEALTH COMPRISING EXTRACTS OF FOR EXAMPLE ROSEMARY OR CARAWAY - Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical having the ability to induce bone morphogenic protein expression. | 02-03-2011 |
| 20110034404 | PEST CONTROL AGENTS - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier: | 02-10-2011 |
| 20110046081 | CLASSICAL CANNABINOID METABOLITES AND METHODS OF USE THEREOF - The present invention encompasses classical cannabinoid metabolites and uses thereof. | 02-24-2011 |
| 20110053872 | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy. | 03-03-2011 |
| 20110053873 | HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 03-03-2011 |
| 20110053874 | USE OF FLAVONOIDE COMPOUNDS FOR THE PROPHYLAXIS AND THERAPY OF ISCHAEMIC OR INFLAMMATORY HEART AND CARDIOVASCULAR DISEASES - The present invention relates to the use of flavonoid compounds, particularly quercetin-3-O-β-D-glucuronide and kaempferol-3-O-β-D-glucuronide and their glucosides, for preventing diseases of the heart. Red vine leaf extract has proved a particularly advantageous source of the flavonoid compounds in question. | 03-03-2011 |
| 20110059912 | COMBINATION THERAPY COMPRISING SGLT INHIBITORS AND DPP4 INHIBITORS - The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes. | 03-10-2011 |
| 20110059913 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL INDICATIONS - The present invention relates to identification of | 03-10-2011 |
| 20110082098 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE - Novobiocin analogues are useful in methods of treating, inhibiting, and/or preventing cyst formation in autosomal dominant polycystic kidney disease (ADPKD) in a subject. The disclosure provides methods of treating ADPKD comprising administering a therapeutically effective amount of a coumarin-3-carboxamide novobiocin analogue. Accordingly, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of mTOR pathway phosphoproteins P-mTOR, P-Akt and P-S6K, or combinations thereof. Further, the method can include administering a novobiocin analogue in a therapeutically effective amount for reducing levels of Hsp-90 client proteins CFTR, ErbB2, c-Raf and Cdk4, or combinations thereof. | 04-07-2011 |
| 20110086810 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE - The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. | 04-14-2011 |
| 20110086811 | HIGH-CONCENTRATION RUTIN-CONTAINING DRINK - It is an object of the present invention to provide a packaged high-concentration rutin-containing drink suppressed the occurrence of the precipitation though it contains rutin in a high concentration. According to the invention, a packaged high-concentration rutin-containing drink includes rutin and quercetin is provided. The concentration of rutin is in a range from 70 to 1100 ppm and the ratio [(A)/(B)] by weight of (A) rutin to (B) quercetin is 3.7 to 58.0. | 04-14-2011 |
| 20110112044 | NOVEL USES OF D-MANNOPYRANOSE DERIVATIVES - The invention relates to the use of mannose-6-phosphate (M6P) and of certain derivatives thereof for controlling angiogenesis and ligament regeneration and/or cartilage reconstruction. The MP6 and certain derivatives thereof can particularly be used for preparing a pharmaceutical composition used for ligament regeneration and/or cartilage reconstruction. | 05-12-2011 |
| 20110130356 | MORPHINE AND MORPHINE PRECURSORS - Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided. | 06-02-2011 |
| 20110136751 | Use of Polyphenols in the Treatment of Cancer - The present invention relates to polyphenol compounds, compositions thereof, and methods for treating or preventing cancer in a subject, the methods comprising co-administering to a subject an effective amount of two or more polyphenol compounds or a polyphenol composition thereof. | 06-09-2011 |
| 20110152210 | POLYPHENOL COMPOUNDS FOR INHIBITING PROTEASOME AND USES THEREOF - Synthetic polyphenolic compounds of formula (I), their modes of synthesis, and pharmaceutical compositions thereof are provided herein. Use of the compounds and compositions described herein for inhibiting proteasomal activity and for treating cancer is also provided. | 06-23-2011 |
| 20110166088 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS - The present invention provides Gyrase B and/or Topoisomerase IV par E inhibitors, which can be used as antibacterial agents. Compounds disclosed herein can be used for treating or preventing conditions caused by or contributed by gram positive, gram negative and anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, | 07-07-2011 |
| 20110166089 | SOLUTION FOR TISSUE ADHESION PREVENTION AND METHOD FOR TISSUE ADHESION PREVENTION - The objective of the invention is to provide a solution for tissue adhesion prevention and a method for tissue adhesion prevention that are applicable to general surgery and in which covering condition during surgery is stable and convenient. The invention is the solution for tissue adhesion prevention of which the active ingredient is trehalose. Also, it contains at least one or more among antioxidants, chelates, antiseptics, hemostatics, anti-inflammatory agents, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides having lubricating properties. This solution for tissue adhesion prevention is provided as any form of perfusion fluid, spray fluid, solution for spray or vaporization administration, foam-like aerosol preparation, injection solution for intravenous fluids, intravenous fluid. | 07-07-2011 |
| 20110183929 | STANDARDIZED EXTRACT AND FRACTION FROM HANCORNIA SPECIOSA LEAVES AND PHARMACEUTICAL COMPOSITION THEREOF - The present invention describes a standardized extract obtained from the leaves of | 07-28-2011 |
| 20110183930 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES - The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application. | 07-28-2011 |
| 20110190228 | SANITISING COMPOSITIONS - The present invention relates to a sanitising composition, particularly to a sanitising composition for combating undesired microorganisms, especially those present on food products such as salads, poultry, cut fruit, and in hospital environments. There is provided a sanitising composition comprising at least one flavonoid, and at least one a surfactant, wherein the composition is acidic. | 08-04-2011 |
| 20110190229 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING - A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others. | 08-04-2011 |
| 20110190230 | Betalain Compositions and Uses Thereof - Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood. | 08-04-2011 |
| 20110201565 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 08-18-2011 |
| 20110207683 | NATURAL COLORANT AND METHODS THEREOF - To provide a material composed mainly of a material derived from dragon fruit having to provide a supplement, a drug, a cosmetic or a food produced by using the material. The invention provides a material derived from dragon fruit, especially, a powder of dragon fruit, and a supplement, a drug, a cosmetic or a food containing the above material as a component. | 08-25-2011 |
| 20110207684 | NEW LOW SIDE EFFECT PHARMACEUTICAL COMPOSITION CONTAINING ISONIAZID - The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds. Said compound was selected from the following groups of compounds: Nordihydroguaiaretic acid, Trans-Cinnamaldehyde, Daidzein, Isovitexin, Kaempferol, disulfuram, β-Myrcene, Quercetin, (−)-Epigallocatechin-3-gallate, (+)-Limonene, Myricetin, Quercitrin, Luteolin-7-Glucoside, Morin, Neohesperidin, Hesperidin, Capillarisin, (−)-Epigallocatechin, Luteolin, Hyperoside, Ethyl Myristate, Tamarixetin, Phloretin, Baicalein, Rutin, Baicalin, Apigenin, Naringenin, Hesperetin, (+)-Epicatechin, (−)-Epicatechin-3-gallat, Isoliquritigenin, Silybin, Vitexin, Genistein, Isorhamnetin, gallic acid, Diosmin, 6-Gingerol, (+)-Taxifolin, Wongonin, Protocatechuic acid, (+)-Catechin, β-naphthoflavone, Embelin, Trans-Cinnamic acid, (−)-Epicatechin, Phloridzin, Puerarin, Umbelliferone, Brij 58, Brij 76, Brij 35, Tween 20, Tween 80, Tween 40, PEG 2000, PEG 400, Pluornic F68, and PEG 4000. The novel, low side-effect compound complex which contains pharmaceutically effective doses of isoniazid (INH), disulfuram (DSF) and/or a third compound, bis-nitrophenyl phosphate (BNPP) can reduce isoniazid (INH)-induced side effects, e.g. hepatotoxicity, etc. | 08-25-2011 |
| 20110218163 | Paeoniflorin Preparations and Uses Thereof for Fat Reduction - Disclosed are methods and preparations useful for reducing fat at a targeted area(s) on a human. The preparations comprise as an active ingredient an adipolysis enhancing (i.e., fat-melting) amount of an active ingredient, paeoniflorin (PF). The preparations may be provided as an injectable preparation or as a topically applied preparation, such as in the form of a crème or lotion. In topical preparations, the active ingredient paeoniflorin may be contained within nanospheres, such as albumin nanospheres. The PF-containing preparations may also include a permeant, such as azone. The method may be accompanied by the application of ultrasound to the area being treated prior to, during or after, or prior to, during, and after application of the paeoniflorin preparation to an area of the body in which fat reduction is desired. By way of example, the methods and preparations are effective for reducing targeted fat deposits at various anatomical sites of the body, such as the midsection (“love handles”), jowls, hips, arms, thighs and buttocks area. | 09-08-2011 |
| 20110218164 | THERAPEUTIC, DIETARY OR COSMETIC USE OF COMPOUNDS WITH SPECIFIC ANTI-APOPTOTIC ACTIVITY TOWARD CASPASE-3, AND COMPOSITIONS CONTAINING THESE COMPOUNDS - This invention regards the use of zeaxanthin and/or rutin, as such or further combined with spermidine, as the active principle in a pharmaceutical, dietary, or cosmetic composition, acting to inhibit caspase-3 and therefore to control apoptosis by preventing programmed cell death. | 09-08-2011 |
| 20110224157 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 09-15-2011 |
| 20110237532 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-- PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL - The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof. | 09-29-2011 |
| 20110237533 | NOVEL POLYPHENOL COMPOUND - Compounds represented by formula (I) | 09-29-2011 |
| 20110251143 | STABLE ELSAMITRUCIN SALT FORMULATIONS - Formulations containing stable forms of elsamitrucin salts are provided. These formulations are useful for treating neoplastic diseases and conditions. | 10-13-2011 |
| 20110251144 | MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 10-13-2011 |
| 20110251145 | Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause - The present invention relates to a pharmaceutical composition for preventing or treating a menopausal symptom, comprising cinnamic acid, shanzhiside methylester or a mixture thereof as an active ingredient. The composition of the present invention exhibits an excellent estrogenic activity, and is effectively utilized for treating or preventing diverse menopausal symptoms generated by estrogen deficiency during perimenopause, menopause and postmenopause. | 10-13-2011 |
| 20110257117 | OLIVE COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONS - A method of treating an inflammatory condition with a hydroxytyrosol-rich composition. Improvement is monitored as a reduction in the levels of a biochemical marker such as homocysteine or C-reactive protein. The composition may be administered in an amount and for a period sufficient to effect a drop in the level of the biochemical marker. | 10-20-2011 |
| 20110257118 | Vascular Circulation in Peripheral and/or Small Blood Vessels - The invention relates to compositions, and methods of use thereof, containing polyphenols such as flavanols, procyanidins, their derivatives and epimers thereof, for improving vascular circulation in peripheral and/or small blood vessels. | 10-20-2011 |
| 20110257119 | Microcirculation improvement and/or treatment - This invention relates to compositions, and methods of use thereof, for improving microcirculation in a diabetic subject, and for dietary management of diabetes-associated condition(s) comprising administering certain polyphenols such as flavanols, procyanidins, or pharmaceutically acceptable salts or derivatives thereof to the subject in need thereof. | 10-20-2011 |
| 20110263519 | REGULATORS OF THE HEDGEHOG PATHWAY, COMPOSITIONS AND USES RELATED THERETO - The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations. | 10-27-2011 |
| 20110275579 | ANTI-DIABETIC EXTRACT OF ROOIBOS - Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention provides an antidiabetic agent, an anti-diabetic composition containing the anti-diabetic agent, a foodstuff or beverage containing the anti-diabetic agent, a method for preventing or treating diabetes or impaired glucose tolerance, and a method of decreasing blood glucose level. The anti-diabetic agent may be an extract from rooibos ( | 11-10-2011 |
| 20110275580 | BICYCLIC DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to compounds of formula (I): | 11-10-2011 |
| 20110275581 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA - A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo IIα have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II. | 11-10-2011 |
| 20110281808 | Composition and Method for Increasing Pre Workout Thermogenics - The present invention provides a composition for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in a mammal, comprising Yerba Mate as a source of caffeine, hordenine and naringin. The present invention further provides a composition for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in a mammal, comprising from 0.0001 g to 0.25 g of caffeine from Yerba Mate leaves, from 0.00001 g to 0.75 g of hordenine from barley and from 0.00001 g to 0.75 g of naringin sourced from grapefruit. The present invention finally provides a method for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in an mammal prior to physical exercise, said method comprising providing a composition comprising a source of caffeine, hordenine and naringin and administering the composition to an mammal prior to physical exercise. | 11-17-2011 |
| 20110288038 | HESPERIDIN-CONTAINING COMPOSITION - This invention relates to a composition that stably contains hesperidin. The present invention provides a composition containing (A) hesperidin, (B) at least one dihydric alcohol selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 3-methyl-1,3-butanediol, and (C) a sugar alcohol. In the composition, the decomposition of hesperidin is suppressed and hesperidin is stably contained. | 11-24-2011 |
| 20110294750 | SURFACE STERILISATION BY MISTING WITH A BIOFLAVANOID SOLUTION - There is described a method of sterilizing surfaces using flavonoids, for example mixtures containing inter alia naringin and neohesperidin, by misting. | 12-01-2011 |
| 20110301107 | DERIVATIVES OF MORPHINE-6-GLUCURONIDE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The disclosure relates to derivatives of morphine-6-glucuronide of formula (I) | 12-08-2011 |
| 20110312904 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES - The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I). | 12-22-2011 |
| 20110312905 | STIMULUS-TRIGGERED PRODRUGS - Set forth herein, inter alia, are compositions and methods for treating diseases with prodrugs. Provided herein are prodrug compositions for inhibiting the function of proteins, compositions and methods for treating diseases associated with oxidative compounds, oxidatively-sensitive prodrugs of inhibitors of metalloproteases. and methods of inhibiting metalloproteases using oxidatively-sensitive prodrugs. | 12-22-2011 |
| 20110312906 | TREATMENT OR REDUCTION OF MENOPAUSAL SYMPTOMS - There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isotlavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isoflavone daidzein, the isotlavone being optionally administered with one or more pharmaceutically acceptable adjuvants, carriers and/or excipients. Therapeutic uses and compositions/foods are also described, comprising daidzein or formononetin optionally in association with one or more pharmaceutically acceptable adjuvants, carriers, food components and/or excipients. | 12-22-2011 |
| 20120004189 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 01-05-2012 |
| 20120022010 | USE OF FLAVONOIDS TO INCREASE THE BIOAVAILABILITY OF HESPERETIN - The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximize the beneficial health effects of hesperetin. | 01-26-2012 |
| 20120040921 | COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING - A composition for use in making commercial food and skin products comprising 5-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism. | 02-16-2012 |
| 20120065153 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF - The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a —OSO | 03-15-2012 |
| 20120071428 | NANOCRYSTALLINE PHOTOCATALYTIC COLLOID, A METHOD OF PRODUCING IT AND ITS USE - The present invention relates to a nanocrystalline photocatalyst active upon visible light irradiation, with a high degree of dispersion, stable in the form of a transparent colloidal solution in an aqueous environment, containing nanocrystals of titanium dioxide (TiO | 03-22-2012 |
| 20120083460 | READILY WATER-SOLUBLE ISOQUERCITRIN COMPOSITION - Disclosed is a method for improving the solubility of isoquercitrin in water. Also disclosed is a readily water-soluble isoquercitrin composition which has improved solubility in water due to the method. Specifically disclosed is a method for preparing an isoquercitrin inclusion product, which comprises including isoquercitrin in γ-cyclodextrin in the proportion of 2 to 10 mol of γ-cyclodextrin to 1 mol of isoquercitrin. | 04-05-2012 |
| 20120083461 | AGENT FOR INHIBITING PERITONEAL MEMBRANE THICKENING | 04-05-2012 |
| 20120094945 | Discovery of Selective Glucocorticoid Receptor Modulators by Multiplexed Reporter Screening - The invention relates to assays to detect selective gene regulation by ligand dependent transcription factors. The invention also relates to selective modulators of the glucocortocoid receptor for treatment of inflammation and allergic and immune-mediated diseases. | 04-19-2012 |
| 20120115800 | Pigment Aggregates - The invention provides a method for in vitro formation of anthocyanic vacuolar inclusion (AVD-like structures, the method comprising the step of combining at least one anthocyanin, and b) at least one lipid. The invention also provides AVI-like structures produced by the method of the invention, compositions comprising such AVI-like structures, and uses of such AVI-like structures. | 05-10-2012 |
| 20120165278 | Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Compositions And Methods For Preparing And Using Same - The present invention relates to pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing pyrroloquinolinyl-pyrrolidine-2,5-dione compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof. | 06-28-2012 |
| 20120184499 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY - The present invention relates to a composition comprising an extract of | 07-19-2012 |
| 20120196818 | METHOD FOR PREPARING POLYPHENOL EXTRACTS FROM SPINACH LEAVES - A method for preparing a concentrated spinach extract in a liquid or dry form and having a polyphenol titer greater than or equal to 50% is described. The method includes a step of purifying a raw spinach extract in a liquid form using a liquid-liquid extraction technique with a food oil. | 08-02-2012 |
| 20120202759 | ISOFLAVONE COMPOSITIONS FOR REDUCING ACCUMULATION OF BODY FAT IN MALE MAMMALS, AND METHODS FOR THEIR USE - Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones. The compositions and methods are particularly useful for the reduction or prevention of body fat accumulation during periods of excess caloric intake, and preferably have a sparing effect on lean body mass. | 08-09-2012 |
| 20120208777 | DIOSMETIN COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 08-16-2012 |
| 20120214755 | METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described. | 08-23-2012 |
| 20120220545 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF - Provided are coumarin compounds of formula I, for example, robustic acid methyl ether, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. | 08-30-2012 |
| 20120225833 | COMPOSITION FOR TREATING MENTAL HEALTH DISORDERS - A composition of three compounds each selected from a selective re-uptake inhibitor of serotonin, a monoamine oxidase inhibitor, and a phosphodiesterase inhibitor, such that all three compounds are different and are naturally occurring. | 09-06-2012 |
| 20120238513 | METHOD FOR INHIBITING ACTIVATION OF MACROPHAGES - Provided is a method for inhibiting the activation of macrophages in a subject, comprising administrating to the subject an effective amount of an active component selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable ester of the compound, and combinations thereof: | 09-20-2012 |
| 20120238514 | NOVEL CRYSTALLINE HETEROAROMATIC FLUOROGLYCOSIDE HYDRATES, PHARMACEUTICALS COMPRISING THESE COMPOUNDS AND THEIR USE - The invention relates to crystalline hydrates of the formula I | 09-20-2012 |
| 20120238515 | METHODS FOR PREVENTING OR TREATING SARCOPENIA AND MUSCLE ATROPHY IN ANIMALS - The invention provides methods for one or more of preventing or treating sarcopenia and muscle atrophy in animals. The methods comprise administering isoflavones to the animals, preferably in amounts of from about 0.001 to about 10 g/kg/day. | 09-20-2012 |
| 20120245111 | FLAVANONES-CONTAINING FOOD COMPOSITIONS - The present invention relates to food products comprising flavanones. In particular, it relates to food products comprising hesperidin having improved stability. The present invention also concerns processes for the manufacturing of food products comprising said flavanones, especially hesperidin and to the use of the food products in the manufacture of compositions for the improvement of bone and skin health. Said flavanones are subjected to heating in water to a temperature of at least 138° C. | 09-27-2012 |
| 20120245112 | SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS - A composition comprising an SL0101 [kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell. | 09-27-2012 |
| 20120245113 | CLERODANE DERIVATIVES FOR MODULATION OF LEUKOTRIENE RECEPTOR ACTIVITY AND RELATED DISEASES - The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments. | 09-27-2012 |
| 20120252745 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES - The disclosure provides novobiocin analogues with noviose replacements which are useful as Hsp90 inhibitors in the treatment of cancer. | 10-04-2012 |
| 20120270818 | HDAC 6 INHIBITOR-BASED METHODS FOR TREATING CANCER - This invention provides methods for treating a subject afflicted with cancer, comprising concurrently administering (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. This invention also provides methods for inducing the death of a transformed cell such as a cancer cell, comprising concurrently contacting the cell with (i) an HDAC 6-selective inhibitor and (ii) a suitable cytotoxic agent such as SAHA, doxorubicin or etoposide. | 10-25-2012 |
| 20120270819 | USE OF COMPOUNDS WITH SGLT-1/SGLT-2 INHIBITOR ACTIVITY FOR PRODUCING MEDICAMENTS FOR TREATMENT OF BONE DISEASE - Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases The invention relates to the use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases like osteoporosis. Preferred is the use of compounds of the formula I in which the radicals have the stated meanings. | 10-25-2012 |
| 20120270820 | USE OF ALBIFLORIN FOR ANTI-DEPRESSION - A pharmaceutical composition containing albiflorin and use thereof in manufacturing medicaments for preventing and treating depression are provided by the present invention. | 10-25-2012 |
| 20120270821 | CDK5 Inhibitors and Therapeutic Uses Thereof - Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of | 10-25-2012 |
| 20120277173 | STABILIZED ANTHOCYANIN COMPOSITIONS - The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not readily undergo degradation, such as oxidation, pH instability, etc. | 11-01-2012 |
| 20120283203 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY, INSULIN RELATED DISEASES AND HYPERCHOLESTEROLEMIA - A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient. | 11-08-2012 |
| 20120283204 | TALARAZOLE METABOLITES - Novel metabolites of talarazole of formula (I) have been isolated and characterized, wherein R═H, OH, OSO | 11-08-2012 |
| 20120295859 | METHOD FOR TREATMENT OF MALARIA - A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound. | 11-22-2012 |
| 20120302515 | METHODS FOR PRODUCING PHYTOEXTRACTS FROM VEGETATION WATERS AND OLIVE OIL POMACES AND COMPOSITIONS OBTAINED THEREBY - Methods are provided for obtaining phytoextracts from vegetation waters and pomaces coming from olive milling. Such methods may be based on combining physical-chemical and enzymatic pre-treatment methods, membrane tangential filtration and vacuum evaporation. Such methods allow eco-sustainable and efficient extraction of the active ingredients involved. Compositions resulting from such methods are also provided. | 11-29-2012 |
| 20120309701 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS - The present invention encompasses compounds and methods for treating urinary tract infections. | 12-06-2012 |
| 20120309702 | DYNAMIC INHIBITORS OF HEAT SHOCK PROTEIN 90 - An inhibitor of heat shock protein 90 (HSP90) can include a coumermycin A1 analog having a structure that inhibits HSP90 greater than coumermycin A1. That is, the coumermycin A1 analog is not coumermycin A1. The coumermycin A1 analog can have an antiproliferative biological activity, which can be superior to coumermycin A1. The activity can include the coumermycin A1 analog inhibiting a C-terminus of HSP90. | 12-06-2012 |
| 20120309703 | AGONISTS OF BITTER TASTE RECEPTORS AND USES THEREOF - The present invention relates to agonists of the human bitter-taste receptors hTAS2R14, hTAS2R10 and hTAS2R4 and their role in bitter taste transduction. The invention also relates to methods for identifying molecules that modulate, e.g. suppress, or enhance hTAS2R14, hTAS2R10 and hTAS2R4 bitter taste transduction or bitter taste response. | 12-06-2012 |
| 20120316123 | DIETARY SUPPLEMENT COMPOSITION OF CITRUS DERIVATIVES - There is disclosed a dietary supplement composition of alkaloids and flavonoids extracted from citrus fruits that exhibits lipolytic and thermogenic activity and increases RMR, while at the same time exhibiting no negative side effects such as increase in blood pressure or heart rate. The composition essentially comprises two components: (A) the protoalkaloids synephrine, tyramine, N-methyltyramine, hordenine and octopamine; and (B) at least one of hesperidin, naringin and mixtures thereof. | 12-13-2012 |
| 20120322754 | NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF - The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of adverse effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system. | 12-20-2012 |
| 20120329739 | COMPOSITION FOR PREVENTING OR TREATING POLIOSIS OR VITILIGO COMPRISING A PUERARIA GENUS PLANT EXTRACT OR PUERARIN - Disclosed is a composition for preventing or treating poliosis or vitiligo comprising a | 12-27-2012 |
| 20130005670 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY - It is described a combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases. | 01-03-2013 |
| 20130012463 | IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS - The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier. | 01-10-2013 |
| 20130018007 | Modified Saponins for the Treatment of Fungal Infections - Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin. | 01-17-2013 |
| 20130023489 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING DISEASES AND ENVIRONMENTALLY INDUCED HEALTH DISORDERS - Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, including an Onaway potato cultivar optionally complemented by a Russet Burbank, Purple Valley or Bora Valley cultivar. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity. | 01-24-2013 |
| 20130035300 | METHOD OF USING POMEGRANATE EXTRACTS FOR INCREASING PROSTATE SPECIFIC ANTIGEN DOUBLING TIME - A method of increasing a prostate specific antigen (PSA) doubling time in treating a patient. A subject with rising serum PSA is selected. A composition is administered to the subject comprising a therapeutically effective amount of a pomegranate extract comprising a higher content of high molecular weight polyphenol compared to pomegranate juice from arils. The therapeutically effective amount increases a prostate specific antigen doubting time. The pomegranate extract is formed from an insoluble byproduct component obtained by placing pomegranate solids in an aqueous solution, heating the aqueous solution to between about 60° F. to about 210° F., adding at least one enzyme to the aqueous solution, and removing residual insoluble solid materials from the aqueous solution. | 02-07-2013 |
| 20130035301 | CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin. | 02-07-2013 |
| 20130045935 | FLAVONOID DIMERS AND THEIR USE - This invention relates to bis-flavonoid compounds of formula | 02-21-2013 |
| 20130065843 | Phenolic Compositions Derived From Apple Skin And Uses Thereof - Described herein are phenolic compositions derived from apple skins. In particular, described herein are flavonoid-rich fractions derived from apple skin extract. The compositions are useful in the prevention and treatment of conditions associated with oxidative stress and/or inflammation, including certain neurodegenerative diseases. Methods of producing the compositions are also described. | 03-14-2013 |
| 20130079294 | EXTRACTS AND ISOLATED FLAVONOIDS FROM EUPHORBIA CUNEATA USEFUL AS ANTI-ULCER AGENTS - The present invention relates to flavonoids isolated from | 03-28-2013 |
| 20130079295 | TREATMENT OF CARTILAGE RESORPTION - Excessive articular cartilage degradation is treated or prevented by administration to a mammal such as a human | 03-28-2013 |
| 20130085114 | METHOD FOR TREATING VARICOCELE OR MALE INFERTILITY USING ANTHOCYANIN EXTRACTED FROM BLACK SOYBEAN - The present invention relates to the therapeutic or ameliorating effects of anthocyanin extracted from black soybean on varicocele or male infertility. In particular, the present invention relates to a method for treating or ameliorating varicocele or male infertility using anthocyanin extracted from black soybean. | 04-04-2013 |
| 20130096075 | COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF METABOLIC SYNDROME - A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein
| 04-18-2013 |
| 20130096076 | PHARMACEUTICAL COMPOSITION COMPRISING A SGLT2 INHIBITOR IN COMBINATION WITH A DPP-IV INHIBITOR - The invention relates to a pharmaceutical composition according to claim | 04-18-2013 |
| 20130109640 | COMPOSITION FOR TREATING OR PREVENTING NEURODEGENERATIVE BRAIN DISEASES COMPRISING BLACK BEAN EXTRACT | 05-02-2013 |
| 20130116204 | (METHYLSULFONYL) ETHYL BENZENE ISOINDOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USES - Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed. | 05-09-2013 |
| 20130123204 | METHOD FOR TREATING HEPATITIS B - The disclosure provides a method for treating hepatitis B, including: administering an effective amount of proanthocyanidins wherein the formula of a monomer of the proanthocyanidins is shown as Formula (I): | 05-16-2013 |
| 20130130998 | Analogues of Etoposide for the Treatment of Tumours - Compounds for treatment of a patient having a tumour that is metastatic and/or that reduces an organ function, wherein the compounds are of the general formula: | 05-23-2013 |
| 20130130999 | METHOD OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS - The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients. | 05-23-2013 |
| 20130131000 | Composition Comprising Ligustroflavone, Rhoifolin and Hyperin and Its Pharmaceutical Application - Disclosed is a composition comprising ligustroflavone, rhoifolin and hyperin, which is prepared according to rational weight ratio: 40% to 80% ligustroflavone, 5% to 45% rhoifolin and 1% to 40% hyperin. The composition can be used as a neuraminidase inhibitor for preventing and treating influenza, and can be formulated into pharmaceutically acceptable dosage forms. | 05-23-2013 |
| 20130137649 | EPIGENETIC MECHANISMS OF ANTI-FIBROTIC ACTION FOR THE LIVER - This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis. | 05-30-2013 |
| 20130150314 | TRIOXACARCINS AND USES THEREOF - The present invention relates to trioxacarcin compounds of the formula: (I) or pharmaceutically acceptable forms thereof; wherein R | 06-13-2013 |
| 20130157966 | NEW USE OF ICARIIN AND EPIMEDIUM FLAVONOIDS CONTAINING ICARIIN - New use of icariin and Epimedium flavaoids containing icariin is provided by the present invention. Specifically, uses of compounds of Formula I or Epimedium containing compounds of formula I, Epimedium flavanoids, or extracts of Epimedium in manufacturing medicaments for treating, preventing, reducing and/or relieving diseases and/or conditoins related to neural myelin sheath impairments, or use of above materials in manufacturing medicaments for relieving demyelination and/or promoting repair of myelin sheath are provided by the present application, wherein, R | 06-20-2013 |
| 20130165396 | Apple Skin Extracts for Treating Cardiovascular Disease - Pharmaceutical and nutraceutical compositions and methods for treating cardiovascular disease, comprising apple skin extracts which can reduce cholesterol levels and inhibit low density lipoprotein (LDL) oxidation in a subject, are provided. | 06-27-2013 |
| 20130184227 | Cytochrome P450 2C9 Inhibitors - This invention is to provide multiple specific inhibitors of cytochrome P450 isozyme CYP2C9. These inhibitors can be derived from any combinations with the following compounds including: Tamarixetin, Formononetin, isoliquritigenin, Phloretin, luteolin, Quercitrin, quercetin, myricetin, Wongonin, Puerarin, Genistein, Nordihydroguaiaretic acid, Narigenin, Capillarisin, Chrysin, Fisefin, eriodictyol, 6-Gingerol, Isorhamneti, isoquercitrin, Morin, (+)-Taxifolin, isovitexin, 3-Phenylpropyl Acetate, Oleanolic acid, ursolic acid, β-Myrcene, cinnamic acid, Luteolin-7-Glucoside, Liquiritin, (+) Limonene, Homoorientin, Swertiamarin, Embelin, Daidzein, Poncirin, (−)-Epicatechin, ergosterol. These natural products can be used to enhance the bioavailability of therapeutic agents (drugs). | 07-18-2013 |
| 20130184228 | MUSCADINE COMPOSITIONS WITH ANTI-OXIDANT ACTIVITY - Antioxidant compositions are disclosed that include muscadine pomace extract and resveratrol from a source other than muscadine. In other examples the composition also includes polyphenols from a source other than muscadine. The compositions increase the expression of antioxidant genes and/or genes associated with mitochondrial biogenesis. | 07-18-2013 |
| 20130190258 | COMPOUNDS FOR INHIBITION OF CANCER CELL PROLIFERATION - Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R | 07-25-2013 |
| 20130196937 | AGE PRODUCTION INHIBITOR - Disclosed is an AGE production inhibitor or the like, which effectively inhibits the production of an advanced glycation end product (AGE), while having improved biological safety. Specifically disclosed is an AGE production inhibitor or the like, which contains en extract of cherry tree (preferably blossoms or leaves thereof) and/or a processed product of the extract as an active substance. The AGE production inhibitor or the like contains, as an active substance, at least one compound that is selected from among 1-O-(E)-Caffeoyl-β-D-glucopyranoside, 1-O-(E)-Coumaroyl-β-D-glucopyranoside, 1-O-(E)-Cinnamoyl-β-D-glucopyranoside, Kaempferol 3-O-β-D-glucopyranoside, Quercetin 3-O-β-D-glucopyranoside, Kaempferol 3-O-(6″-malony)-β-D-glucopyranoside, and Quercetin 3-O-(6″-malony)-β-D-glucopyranoside. | 08-01-2013 |
| 20130196938 | COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT - A first aspect of the invention relates to a combination comprising 2′-cyano-2′-deoxy-N | 08-01-2013 |
| 20130210753 | METHODS OF TREATING MUSCULAR DYSTROPHIES - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group. | 08-15-2013 |
| 20130210754 | METHOD FOR PRODUCING AN ENRICHED EXTRACT FROM VITIS VINIFERA L. LEAVES - The present application relates to a process for preparing an extract of leaves of | 08-15-2013 |
| 20130231297 | DIETARY SUPPLEMENT FOR IMPROVING VISUAL PERFORMANCE - An orally administered composition and method for improving visual performance using the composition is provided. The composition comprises a combination of astaxanthin, saffron, lutein, zeaxanthin and European black currant extract in amounts effective to reduce eye fatigue or enhance at least one of visual acuity, contrast acuity, glare relief and recovery, or high intensity blue light filtration. | 09-05-2013 |
| 20130244961 | ABNORMAL INTRAOCULAR PRESSURE TREATMENT - Methods and compositions for reducing intraocular pressure in a patient, particularly a human patient, are described. In particular, compositions are disclosed that contain an anthocyanoside or an extract comprising it, a proanthhocyanidin or an extract comprising it and combinations thereof. The compositions are useful for lowering intraocular pressure. | 09-19-2013 |
| 20130252911 | COMPOSITIONS COMPRISING FLAVONOID-CONTAINING EXTRACTS FROM PLANTS OF THE GENUS CITRUS AND/OR ISOLATED CITRUS FLAVONOIDS AND SPECIFIC CATIONIC SURFACE ACTIVE AGENTS, AND SAID COMPOSITION FOR USE AS AN AGENT FOR TREATING INFESTATIONS WITH HEAD LICE - A composition having anti-lice properties comprising effective amounts of at least one monoalkyl and/or dialkyl quat and/or amidoquat in combination with flavonoid-containing extracts obtained from | 09-26-2013 |
| 20130261068 | COMPOSITIONS AND METHOD FOR IMPROVING ENDOTHELIAL FUNCTION AND CARDIOVASCULAR HEALTH - Compositions of natural antioxidants, especially those derived from | 10-03-2013 |
| 20130274211 | BIOCOMPATIBLE, NON-BIODEGRADABLE, NON-TOXIC POLYMER USEFUL FOR NANOPARTICLE PHARMACEUTICAL COMPOSITIONS - The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds. | 10-17-2013 |
| 20130274212 | Sesterterpene Compounds and Use Thereof - The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed. | 10-17-2013 |
| 20130274213 | GLYCOSYLATED AMINOCOUMARINS AND METHODS OF PREPARING AND USES OF SAME - There is provided a method of glycosylating an aminocoumarin compound comprising conjugating a sugar to the 4′-OH position of the core of the aminocoumarin compound. Also provided is an aminocoumarin compound glycosylated at the 4′-OH position of the core of the aminocoumarin compound. Further aspects of this invention provide this compound for use in therapy, more particularly for use as an antibiotic, or in anticancer treatment. | 10-17-2013 |
| 20130281389 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA - Topoisomerase II alpha (topo IIα) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo IIα is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo IIα to the export receptor CRM1. Inhibition was specific to topo IIα as p53 trafficking was unaffected along with topo IIα protein expression and function (decatenation). These topo IIα-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor. | 10-24-2013 |
| 20130288989 | NEW USE OF CHEMICAL INGREDIENTS IN CYNOMORIUM AS PHYTOESTROGEN - Use of chemical ingredients in | 10-31-2013 |
| 20130303471 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 11-14-2013 |
| 20130316966 | USE OF ALBIFLORIN AND METABOLITES THEREOF - Disclosed is a use of albiflorin or a metabolite thereof in preparation of antianxiety and sleep disorder improving drugs or health-care food. Tests prove that albiflorin has significant antianxiety effects and sleep disorder improving effects achieved by prolonging SWS and low the toxic side effects, thus being a safety monomer compound capable of effectively treating anxiety and sleep disorder. | 11-28-2013 |
| 20130324487 | Cyanidin-3-glucoside and Methods for Using the Same - The present invention provides diet supplement compositions comprising cyanidin-3-glucoside (C3G) or C3G source or extracts and methods for using the same to aid in bodily fat loss. | 12-05-2013 |
| 20130338089 | METHODS AND COMPOUNDS FOR MODULATING THE SECRETION OR EXPRESSION OF ADHESION PROTEINS OR ANGIOPOIETINS OF CELLS - This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer. | 12-19-2013 |
| 20130338090 | Novel Compound Isolated from Allium tuberosum and Use Thereof as Antiviral Agent - The present invention relates to a novel compound isolated from | 12-19-2013 |
| 20130345157 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROP- ANENITRILE - The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. | 12-26-2013 |
| 20130345158 | COMPOSITION FOR PROMOTING HEMATOGENESIS CONTAINING QUERCETIN 3-O-beta-(2''-GALLOYL)-RHAMNOPYRANOSIDE AS ACTIVE INGREDIENT - This invention relates to a composition for promoting hematopoiesis and for treating, preventing or alleviating cytopenia or bone marrow failure comprising quercetin 3-O-β-(2″-galloyl)-rhamnopyranoside (QGR) as active ingredient. The present active compound QGR (i) increases dose dependently the mRNA expression of cytokines involved in hematopoiesis including stem cell factor, granulocyte-macrophage colony stimulating factor and erythropoietin from mouse bone marrow mononuclear cells, (ii) promotes the formation of burst forming unit-erythroid and colony forming unit-fibroblast, (iii) stimulates the generation of cells positive for TER-119, a specific marker of mouse erythroid precursors, (iv) promotes erythropoiesis, leukopoiesis, thrombopoiesis, and hemoglobin production in bone marrow failure mouse model, (v) stimulates the formation of hematopoietic stem/progenitor cells and mesenchymal stem/progenitor cells, (vi) stimulates megakaryocyte formation surrounding the blood system of damaged bone marrow, osteoid formation and bone marrow restoration through a recovery of damaged bone marrow microenvironment. The QGR of the present invention can be used for promoting hematopoiesis and treating cytopenia or bone marrow failure. | 12-26-2013 |
| 20140018310 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY - A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases. | 01-16-2014 |
| 20140018311 | MUSCADINE COMPOSITIONS WITH IMPROVED ANTI-OXIDANT ACTIVITY - Disclosed is a composition for use as an antioxidant, such as for use as an anti-aging supplement. The composition can include a muscadine ( | 01-16-2014 |
| 20140038913 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 02-06-2014 |
| 20140045777 | METHOD OF INHIBITING PREMATURE AGING OF HUMAN SKIN CAUSED BY EXPOSURE TO INFRARED RADIATION - A method of inhibiting premature aging of human skin caused by exposure to infrared radiation comprising contacting the skin with a composition containing a therapeutically-effective amount of at least one protective compound chosen from baicalin, phloretin and neohesperidin dihydrochalcone, as well as combinations thereof. | 02-13-2014 |
| 20140045778 | PEST CONTROL AGENTS - Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier: | 02-13-2014 |
| 20140057860 | PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES AND METHOD OF MANUFACTURING THE SAME - The present invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and the method of preparation thereof. The aforesaid pharmaceutical composition is prepared by the following components in weight percent: 0.1%-0.3% scutellarin, 20%-25% co-surfactant, 40-50% surfactant, and 25-30% oil. The method of preparing the aforesaid pharmaceutical composition comprises the steps of: (1) dispersing scutellarin in co-surfactant and surfactant to obtain a mixture; (2) dispersing the mixture from step (1) in oil, and thermostatically and magnetically stirring the dispersion mixture under the temperature of 25° C. to 37° C., such that the components thereof are completely dissolved to obtain the pharmaceutical composition. Through the use of the selected pharmaceutical adjuvants having the ability to inhibit MRP2, the aforesaid pharmaceutical composition effectively improves absorption and bioavailability of scutellarin. The preparation of the aforesaid pharmaceutical composition is simple and convenient, and the pharmaceutical composition can be processed into a variety of dosage forms for oral administration. | 02-27-2014 |
| 20140080773 | Composition for Delivering an Anti-Ageing Effect on the Skin and a Method for Improving Skin Characteristics - A composition suitable to improve skin characteristics is described along with a regimen to improve skin characteristics. The composition is not limited to format, and can be in the form of a capsule, tablet or food product. When consumed within a defined regimen, the composition with active mixture results in skin that is smoother and with a reduction in wrinkles. | 03-20-2014 |
| 20140080774 | IDENTIFICATION OF FREE-B-RING FLAVONOIDS AS POTENT COX-2 INHIBITORS - The present invention provides a novel method for inhibiting the cyclooxygenase enzyme COX-2. The method is comprised of administering a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 mediated diseases and conditions. The method for preventing and treating COX-2 mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition containing a Free-B-Ring flavonoid or a composition containing a mixture of Free-B-Ring flavonoids and a pharmaceutically acceptable carrier. | 03-20-2014 |
| 20140080775 | MOLECULAR MODULATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed. | 03-20-2014 |
| 20140080776 | COMPOSITION AND METHODS FOR EXTRACTING AND USING PHYTOCHEMICALS FOR THE TREATMENT OF INFLUENZA - Methods and compositions for treating at least one symptom of a viral infection, said method of treatment comprising administering to a subject with a least one symptom of a viral infection an effective dosage unit of a composition comprising pomegranate extract. The compositions comprise pomegranate extract comprising polyphenols. The composition is produced by a process comprising providing one or more pomegranate solids selected from the group consisting of a pericarp, inner membrane and seeds, creating a mixture comprising said one or more pomegranate solids in an aqueous solution, heating said mixture to a temperature that permits enzyme catalysis of said pomegranate solids, and removing residual insoluble solid materials from said mixture to provide said pomegranate extract. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements. | 03-20-2014 |
| 20140088030 | WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES - The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-α-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application. | 03-27-2014 |
| 20140100178 | COMPOSITION AND METHODS FOR SITE-SPECIFIC DRUG DELIVERY TO TREAT MALARIA AND OTHER LIVER DISEASES - A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (D-L-A-D1). The linker includes a functional group that is recognized and cleaved by enzyme in the target phases. The recognition segment is preferably a malaria drugs. The carrier is preferably hydrophilic, biodegradable and biocompatible particle. Any drug may be delivered using a conjugate prepared according to the invention. | 04-10-2014 |
| 20140100179 | NOVEL UREA COMPOUNDS - The present invention provides a compound of Formula I: | 04-10-2014 |
| 20140107046 | COSMETIC COMPOSITIONS CONTAINING AT LEAST ONE FLAVONOID AND FERULIC ACID - The invention provides synergistic aqueous compositions comprising at least one flavonoid, and ferulic acid, and optionally one or more additional antioxidants, for cosmetic use. | 04-17-2014 |
| 20140107047 | COSMETIC COMPOSITIONS FOR INCREASING BIOAVAILABILITY OF ACTIVE COMPOUNDS - Aqueous compositions comprising a) at least one active compound and b) at least one hydrotrope in an amount effective to increase transdermal penetration of the active compound, and methods for increasing bioavailability of active compounds are provided. | 04-17-2014 |
| 20140107048 | COMPOSITIONS CONTAINING PHENOLIC COMPOUNDS AND HYDROTROPES FOR COSMETIC USE - Aqueous compositions comprising (a) at least one phenolic compound and (b) at least one hydrotrope in an amount effective to solubilize said at least one phenolic compound in water are provided for cosmetic and other uses. | 04-17-2014 |
| 20140107049 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS - The present invention relates to compounds useful for the treatment or prevention of bacteria infections. The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. The invention also provides processes for making the compounds of the invention. | 04-17-2014 |
| 20140107050 | INCREASING BIOAVAILABILITY OF N-COUMAROYLDOPAMINE THROUGH CO-ADMINISTRATION WITH A CATECHOL-O-MEHTYLTRANSFERASE (COMT) INHIBITOR - The present invention is directed to a composition including N-Coumaroyldopamine and a catechol-o-methyltransferase (COMT) inhibitor for promoting weight loss in a user. | 04-17-2014 |
| 20140107051 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. | 04-17-2014 |
| 20140107052 | EDIBLE COMPOSITION - Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition is provided, the composition comprising at least 5% dry weight at least one flavonoid aglycone and at least 5% dry weight at least one flavonoid glucoside, wherein the flavonoid glucoside is at least 20%, preferably at least 40%, most preferably at least 60% more resistant to hydrolysis by lactase phloridzin hydrolase than quercetin-4-glucoside, and wherein the flavonoid aglycone is a GLUT 2 inhibitor and the flavonoid glucoside is a SGLT 1 inhibitor. | 04-17-2014 |
| 20140107053 | APPLES WITH HIGH POLYPHENOLIC CONTENT - The invention relates to apples comprising high concentrations of polyphenols, to processes for obtaining said apples and to uses of apples as a method of treatment of prophylaxis of cardiovascular disease, colon cancer and digestive health. | 04-17-2014 |
| 20140113878 | COMPOSITIONS COMPRISING NORIBOGAINE AND AN EXCIPIENT TO FACILITATE TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier. | 04-24-2014 |
| 20140128333 | Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release - The present invention relates to methods for decreasing intestinal glucose uptake and inducing incretin release in a human subject, entailing the activation of human G protein-coupled receptor GPR40 (a receptor expressed in human intestinal L-cells) by administering one or more anthocyanin or anthocyanidin compounds, preferably one or more delphinidin compounds, in an amount effective for the activation of GPR40 and the induction of incretin. | 05-08-2014 |
| 20140148399 | Compositions and methods for treating or ameliorating obesity or for reducing diabetic hypercholesterolemia - Obesity is one of the major health concerns in the Twenty-First Century and is one of the leading causes of preventable death. It is a strong risk factor for Type 2 Diabetes. Disclosed herein are compositions and methods using | 05-29-2014 |
| 20140148400 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY - Derivatized coumarin-based pharmaceutical compositions and methods to use them are provided. The compositions are characterized in that they inhibit the activity of tumor-related CAIX and CAXII to a greater degree than they inhibit the activity of CAI and CAII. The compositions can be used to suppress tumor growth and/or suppress tumor metastases in a mammal. | 05-29-2014 |
| 20140148401 | COMBINATION OF CAROTENOID, PHYTOOESTROGEN AND VITAMIN C FOR MOISTURIZING THE SKIN - The present invention relates to the use of a combination (i) of at least one carotenoid, (ii) of at least one phytooestrogen, and (iii) of vitamin C, as an active agent for moisturizing the skin, for the preparation of a cosmetic composition that is suitable for orally administering a daily dose of from 1 to 25 mg of the said carotenoid, from 10 to 300 mg of a phytooestrogen and from 10 to 1000 mg of vitamin C. | 05-29-2014 |
| 20140155339 | HYDROXYTYROSOL AND OLEUROPEIN COMPOSITIONS FOR INDUCTION OF DNA DAMAGE, CELL DEATH AND LSD1 INHIBITION - Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided. | 06-05-2014 |
| 20140155340 | GEL BASED LIVESTOCK FEED, METHOD OF MANUFACTURE AND USE - A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component is solubilized or the sequestrates affecting the reactivity between the alginate and the calcium component is removed such that a gel feed is formed that includes a gel matrix containing the feed nutrient components. The gel feed may then be fed to the livestock. In another aspect of the present invention, piglets are weaned by feeding the gel feed for at least seven days directly after weaning. The gel feed may also include protein derived from blood with or without egg protein. | 06-05-2014 |
| 20140162967 | NOVEL PYRAZOLE COMPOUNDS - The present invention provides a compound of Formula II: | 06-12-2014 |
| 20140162968 | METHOD FOR SCREENING OF AGENT FOR TREATING OR PREVENTING OBESITY - The present invention relates to a method for screening and preparing an obesity prevention or treatment agent, and a method for preparing an obesity prevention or treatment agent. Being able to easily detect a substance that has a preventive and therapeutic effect on obesity, the present invention has a wide spectrum of applications in the research and medicine field in the prevention or treatment of obesity. | 06-12-2014 |
| 20140187506 | Inhibitors of Advanced Glycation End Products - The present invention provides compounds of the formula, | 07-03-2014 |
| 20140194372 | HEART FAILURE SUPPRESSING AGENT - Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient. | 07-10-2014 |
| 20140194373 | COSMETIC USE OF HESPERIDIN OR A DERIVATIVE THEREOF IN THE PREVENTION AND/OR TREATMENT OF BODY ODOUR - The present invention relates to the cosmetic use, in particular the oral use, of at least an effective amount of hesperidin or a derivative thereof as a deodorant agent. | 07-10-2014 |
| 20140213538 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided. | 07-31-2014 |
| 20140249095 | Method for Inhibiting Spinocerebellar Ataxia - A method for inhibiting spinocerebellar ataxia is disclosed, which comprises: administering an extract of | 09-04-2014 |
| 20140288016 | METHOD OF PROVIDING AN ANTI-ULCER TREATMENT WITH EXTRACTS AND ISOLATED FLAVONOIDS FROM EUPHORBIA CUNEATA - The present invention relates to methods of isolating flavonoids from | 09-25-2014 |
| 20140288017 | CATECHOL DIETHERS AS POTENT ANTI-HIV AGENTS - The present invention is directed to novel catechol diether compounds, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV 1 and 2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection. | 09-25-2014 |
| 20140296171 | NOVEL UREA COMPOUNDS - The present invention provides a compound of Formula I: | 10-02-2014 |
| 20140303103 | CARBONIC ANHYDRASE IX-RELATED MARKERS AND USE THEREOF - The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors. | 10-09-2014 |
| 20140309180 | XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I | 10-16-2014 |
| 20140309181 | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES - Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented. | 10-16-2014 |
| 20140315837 | COMPOSITIONS COMPRISING NORIBOGAINE AND AN EXCIPIENT TO FACILITATE TRANSPORT ACROSS THE BLOOD BRAIN BARRIER - This invention relates generally to compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier. | 10-23-2014 |
| 20140329767 | Compositions and Methods for Preventing and Treating Diseases and Environmentally Induced Health Disorders - Nutraceutical or pharmaceutical compositions, functional foods, extracts, dietary supplements and food/feed additives enriched in phytochemicals having antioxidant and/or anti-inflammatory activity may be derived from the skin, pith, or cortex from stem tubers of select potato cultivars, such as Onaway, Russet Burbank, Purple Valley or Bora Valley cultivars. These cultivars and combinations thereof provide a useful antioxidant source enriched in ferulic acid, caffeic acid, chlorogenic acids, ascorbic acid, anthocyanins, and rutin, isomers or derivatives thereof having antioxidant and/or anti-inflammatory activity. | 11-06-2014 |
| 20140343001 | INDOLE DERIVATIVES INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) - The present invention encompasses compounds having general formula (I) able to inhibit the lactate production (lactic acid) involved in the angiogenesis of tumoral tissues, in the glycolytic metabolic process of tumoral cells, of immune system cells in asthmatic diseases, in vascular cells in the pulmonary hypertension, in the treatment of chronic back pain or hyperoxaluria, and in the process by which the parasites protozoan causing malaria obtain most of the necessary energy. | 11-20-2014 |
| 20140343002 | METHOD OF LOWERING GLYCEMIC INDEX OF FOODS - A method of delaying digestion by an animal or a human of carbohydrates in food, comprising administering an effective amount of one or more flavonoids to the animal or human in conjunction with the food, wherein the flavonoids are selected from luteolin, apigenin, tricin and their pharmaceutically acceptable analogues and derivatives. | 11-20-2014 |
| 20140357583 | Sugar Extracts - This invention relates to novel extracts from sugar cane and sugar beet molasses and the characterisation of those extracts. The extracts are enriched in hydrophobic compounds including polyphenols, in levels 5 to 10 fold higher than found in molasses itself. Methods for extracting the extract are also described, together with new uses for the extracts as food ingredients, food modifiers and therapeutic substances. | 12-04-2014 |
| 20140357584 | ARYL NAPHTHALIDE LIGNANS AS ANTI-HIV AGENTS - Provided herein are glycosidic aryl naphthalide lignans compounds, such as justiprocumin A isolated from the plant | 12-04-2014 |
| 20140364382 | COMPOSITION FOR INHIBITING LIVER FUNCTION DETERIORATION, CONTAINING CITRUS PEEL EXTRACT OR NARIRUTIN AS ACTIVE INGREDIENT, AND METHOD FOR EXTRACTING NARIRUTIN FROM CITRUS PEEL - The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for preventing and treating liver diseases. In addition, the present invention relates to a method for extracting narirutin from citrus peel, and a method for preparing citrus fermented milk using the same. | 12-11-2014 |
| 20140378400 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROP- ANENITRILE - The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile. | 12-25-2014 |
| 20150025027 | Combination of a Monosubstituted Sulfamate Derivate of the Natural Monosaccharide d-Fructose (Topiramate) with an Anti-Depressant from the Phenyl Ketone Class (Bupropion) for Treating Obesity and Plurimetabolic Syndromes - Combination of a monosubstituted sulfamate derivate of the natural monosaccharide d-Fructose (Topiramate) with an anti-depressant from the phenyl ketone class (Bupropion) for treating obesity and plurimetabolic syndromes, which takes into consideration “Combined Therapy”, using two drugs (topiramate and bupropion) with different action mechanisms, with the intent of promoting a synergistic effect on weight loss. The solid pharmaceutical form contains from 75 to 400 mg of bupropion chlorohydrate combined with 25 to 200 mg of topiramate; the presential are added in the formulation until q.s.p 1 pill/coated pill. | 01-22-2015 |
| 20150031639 | NEW C-GLYCOSYLPOLYPHENOL ANTIDIABETIC AGENTS, EFFECT ON GLUCOSE TOLERANCE AND INTERACTION WITH BETA-AMYLOID. THERAPEUTIC APPLICATIONS OF THE SYNTHESIZED AGENT(S) AND OF GENISTA TENERA ETHYL ACETATE EXTRACTS CONTAINING SOME OF THOSE AGENTS - The present invention concerns the antidiabetic-activity of compounds type A, namely of 8-β-D-glucosylgenistein, which is not toxic to eukaryotic cells and has demonstrated to produce complete normalization of fasting hyperglycaemia, to reduce excessive postprandial glucose excursion, to increase glucose-induced insulin secretion and insulin sensitivity. An alternative synthesis for this molecular entity and its binding ability to β-amyloid oligomers is also included in the present invention, which also comprises | 01-29-2015 |
| 20150065441 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF COGNITIVE FUNCTION DISORDERS COMPRISING SPINOSYN - The pharmaceutical composition of the present invention, which comprises spinosin or a spinosin-containing herbal extract, is a composition for preventing and treating cognitive function disorders, and can effectively improve memory and learning ability, and effectively treat and prevent cognitive function disorders such as dementia and amnesia. | 03-05-2015 |
| 20150072945 | Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same - Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions. | 03-12-2015 |
| 20150087607 | MICRORNA COMPOSITIONS AND METHODS - Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer. | 03-26-2015 |
| 20150105338 | THERAPEUTIC COMPOSITIONS COMPRISING PHENOLIC ACIDS FOR TREATING CONDITIONS RELATED TO INAPPROPRIATE PLATELET AGGREGATION - The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C | 04-16-2015 |
| 20150111844 | POLYPHENOL COMPOSITION - A polyphenol composition derived from | 04-23-2015 |
| 20150119347 | COMPOSITION FOR PREVENTING OR TREATING HAIR LOSS OR PROMOTING HAIR GROWTH COMPRISING SECOIRIDOID GLUCOSIDE DERIVATIVES - The present invention provides a method for preventing or treating hair loss or promoting hair growth, comprising secoiridoid glucoside derivatives or hydrolysate thereof as active ingredients. The present invention not only includes natural compounds as an active ingredient without side effects of the long-term treatment in a chronic disease hair loss, but also shows excellent effects for promoting hair growth with stable efficacy. Therefore, the present invention may be used as an effective pharmaceutical, cosmetic or functional food composition for preventing or treating hair loss or promoting hair growth. | 04-30-2015 |
| 20150119348 | CDK5 Inhibitors and Therapeutic Uses Thereof - Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of | 04-30-2015 |
| 20150126465 | PROCESS FOR PRODUCING DERIVATIVES OF PYROSTEGIA VENUSTA, DERIVATIVES OF PYROSTEGIA VENUSTA, PHARMACEUTICAL COMPOSITIONS AND ITS USES - The present invention relates to the process for producing compounds derived from the plant | 05-07-2015 |
| 20150141355 | SALACIA COMPOSITIONS, METHODS OF TREATMENT BY THEIR ADMINISTRATION, AND METHODS OF THEIR PREPARATION | 05-21-2015 |
| 20150290231 | COMPOSITION FOR INHIBITING CELLULAR SENESCENCE COMPRISING QUERCETIN-3-O-beta-D-GLUCURONIDE - The present invention relates to a composition for inhibiting cellular senescence comprising quercetin-3-O-β-D-glucuronide (Q3GA) as an active ingredient, and provides a composition for inhibiting cellular senescence of fibroblasts or umbilical vein endothelial cells induced by adriamycin or replicative senescence of fibroblasts or umbilical vein endothelial cells. Specifically, the quercetin-3-O-β-D-glucuronide (Q3GA) is characterized by being isolated from | 10-15-2015 |
| 20150290232 | DRUG COMPOSITION FOR TREATING TUMORS AND APPLICATION THEREOF - The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combination, and particularly relates to pharmaceutical combination of bisbenzylisoquinoline alkaloids (e.g. berbamine and tetrandrine) and anthracene compounds (e.g. aclarubicin A) and their use in treating tumors. | 10-15-2015 |
| 20150290265 | COMPOSITION FOR TREATING METABOLIC DISORDERS - The present invention relates to a herbal composition comprising a therapeutically effective amount of an extract of the plant | 10-15-2015 |
| 20150306122 | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF - In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing or delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug). | 10-29-2015 |
| 20150313927 | AN EDIBLE COMPOSITION COMPRISING RESVERATROL AND FLAVONOID MONOGLUCOSIDE - Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. In a first aspect of the invention, an edible composition is provided, in the form of a single serving of one or more unit dosages, wherein the edible composition comprises 20-2000, preferably 30-1000, most preferably 40-500 mg a 3,5-dihydroxy-trans-stilbene and 10-2000, preferably 20-1000, most preferably 40-500 mg flavonoid mono-glucoside or dihydrochalcone monoglucoside. | 11-05-2015 |
| 20150313928 | NEW APPLICATION OF CATALPOL - A novel usage of catalpol. The novel usage refers to the application of catalpol in the preparation of a drug or health food for treatment of hyperthyroidism, and to the application of catalpol in the preparation of a drug or health food for treatment of hyperthyroidism related cardiopathy | 11-05-2015 |
| 20150320779 | METHODS AND ASSAYS FOR COMBINATION TREATMENT OF CANCER - The technology described herein is directed to the treatment of cancer, e.g. methods and assays relating to selecting and administering a chemotherapy with or without an EZH2 inhibitor. | 11-12-2015 |
| 20150322106 | SOLID BETALAIN COMPOSITIONS AND METHODS - Solid, free-flowing, and substantially completely dissolvable preparations with high betalain content are presented. Most typically, the betalain profile of the preparations is near natural and includes betalains in an amount of between 10-40 wt %. As the preparations of the inventive subject matter maintain chemical stability and flowability over extended periods of time, it should be noted that the betalain preparations are now amenable to compounding in small and measured quantities. Furthermore, new biological activities of betalains are shown, and especially include significant induction of SIRT and reduction of serum triglyceride. | 11-12-2015 |
| 20150328245 | Agents for Eliminating Tumour-Initiating Cells - The present invention provides agents useful for eliminating tumour initiating cells, compositions thereof, uses thereof and methods of using the same. | 11-19-2015 |
| 20150335673 | METHOD FOR PRODUCING POLYPHENOL COMPOSITION - Provided is a method for easily producing a polyphenol composition in a solid state having an excellent solubility in water. The method for producing the polyphenol composition comprises the following steps (1) and (2): (1) heating a mixture of a hardly water-soluble polyphenol (A) and a water-soluble polyphenol (B) to a temperature equal to or higher than the lowest melting point or glass transition temperature of the hardly water-soluble polyphenol (A) or the water-soluble polyphenol (B), thereby obtaining a heat-treated solution, and (2) cooling and solidifying the thus-obtained heat-treated solution. | 11-26-2015 |
| 20150342903 | HYDROXYTYROSOL AND OLEUROPEIN COMPOSITIONS FOR INDUCTION OF DNA DAMAGE, CELL DEATH AND LSD1 INHIBITION - Compositions comprising hydroxytyrosol-containing formulations and treatment regiments comprising hydroxytyrosol and/or oleuropein and chemotherapeutic agents are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, such as a malignancy, and for inducing or enhancing angiogenesis, treating or preventing oxidative stress, for treating or preventing high glucose-induced dysfunction, treating or preventing chemotherapy-induced dysfunction, and for improving cell viability are provided. Various methods for use of the hydroxytyrosol compositions for inhibition of lysine specific demethylase 1 (LSD1) in various cancers are also provided. | 12-03-2015 |
| 20160000754 | Antiviral Activity from Medicinal Mushrooms and their Active Constituents - Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health. | 01-07-2016 |
| 20160008313 | COMPOSITIONS FOR ANTI-INFLAMMATORY, ANTIOXIDANT EFFECTS AND IMPROVED RESPIRATORY FUNCTION BY SPECIFIC HISTONE DEACETYLASE INHIBITION | 01-14-2016 |
| 20160021881 | ANTI-MICROBIAL COMPOSITIONS - Antimicrobial compounds from | 01-28-2016 |
| 20160022642 | Compounds Useful for Promoting Protein Degradation and Methods Using Same - The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the description comprises an androgen receptor. Compounds of the present description may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state. | 01-28-2016 |
| 20160022720 | COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES ASSOCIATED WITH ACTIVATED T CELLS AND/OR B CELLS - Disclosed are combination therapies and related compositions that may contain one or more of a p53 potentiating agent, a DNA-damaging agent, an agent that inhibits cell cycle check point, and a pharmaceutically acceptable carrier. Also disclosed are methods of using such compositions for the treatment of conditions related to T cell and/or B cell activation in subjects in need of such treatment. | 01-28-2016 |
| 20160022721 | ETOPOSIDE AND PRODRUGS THEREOF FOR USE IN TARGETING CANCER STEM CELLS - The present invention pertains to the use of podophyllotox in derivatives, such as CAP7.1, in methods for inhibition of and/or prevention of the growth and/or survival of cancer stem cells. The invention discloses the surprisingly specific activity of the compounds in accordance with the invention against a cancer stem cell population. In this respect the present invention provides the use of the compounds as described in the treatment of cancer, specifically of cancers which have a high risk of developing metastases, chemotherapeutic resistances and/or cancer relapse. Provided are novel methods of cancer treatment, and pharmaceutical compositions comprising the compounds as described, for use in such treatment methods. | 01-28-2016 |
| 20160030457 | TUMOR-SELECTIVE COMBINATION THERAPY - The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of NQO1. | 02-04-2016 |
| 20160038526 | TREATMENT OF PROSTATE CANCER - Prostate cancer is treated by administration of N | 02-11-2016 |
| 20160039775 | RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS - Disclosed herein are resorufin derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. | 02-11-2016 |
| 20160045519 | COMPOSITIONS FOR USE IN STIMULATING BONE GROWTH - The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders. | 02-18-2016 |
| 20160051612 | THE COMPOSITION COMPRISING A PURIFIED EXTRACT ISOLATED FROM PSEUDOLYSIMACHION ROTUNDUM VAR. SUBINTEGRUM CONTAINING ABUNDANT AMOUNT OF ACTIVE INGREDIENT OR THE COMPOUNDS ISOLATED THEREFROM, AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND THE USE THEREOF - A composition comprising a purified extract isolated from | 02-25-2016 |
| 20160058713 | METHODS OF MAKING A DEUTERATED OR A NON-DEUTERATED MOLECULE AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT - Deuterated and non-deuterated forms of tetrahydrocurcumin are described herein. Methods of making tetrahydrocurcumin in deuterated and non-deuterated forms and pharmaceutical formulations including tetrahydrocurcumin in deuterated and non-deuterated forms are disclosed. Methods of treating a subject using deuterated forms of tetrahydrocurcumin or non-deuterated forms of tetrahydrocurcumin are also disclosed. | 03-03-2016 |
| 20160067201 | COMPOSITIONS AND METHODS FOR THE REDUCTION OR PREVENTION OF HEPATIC STEATOSIS - Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein. | 03-10-2016 |
| 20160082147 | IMPLANTS FOR INDUCING SOFT AND HARD TISSUE INTEGRATION - The present invention provides a biocompatible implant comprising one or more metal(s), metal alloy(s), metal oxide(s) or a combination thereof, wherein an antioxidant compound selected from the group of flavonoids or methoxytryptophols, an ester thereof, a pharmaceutically acceptable salt thereof or a combination thereof, is/are coated to at least a part of a metal, metal alloy or metal oxide surface of said biocompatible implant. This implant is useful for replace bone tissue in vertebrate animals, and furthermore restore the normal function of said tissue, mainly due to its ability of induce osseointegration and soft tissue attachment. | 03-24-2016 |
| 20160095874 | METHOD OF DETERMINING ACUTE MYELOID LEUKEMIA RESPONSE TO TREATMENT WITH FARNESYLTRANSFERASE INHIBITORS - The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients. | 04-07-2016 |
| 20160106770 | EPIGENETIC MECHANISMS OF ANTI-FIBROTIC ACTION FOR THE LIVER - This invention demonstrates the therapeutic efficacy of Yang-Gan-Wan (YGW) and its active components, especially in the formulation provided by Sheng-Pu Pharmaceutials, Inc., for treating and preventing liver fibrosis. This invention further demonstrates MeCP2 is an important therapeutic target for YGW and its active ingredients' action against liver fibrosis and cirrhosis. | 04-21-2016 |
| 20160129031 | PYRAZOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES - The present invention provides pyrazole derivatives, uses thereof for medical purposes and so on. More particularly, the present invention relates to pharmaceuticals useful for the prevention or treatment of constipation, which comprise as an active ingredient 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl]-3-methylphenoxy}propylamino)-2,2-dimethylpropionamide, or a pharmaceutically acceptable salt thereof. The pharmaceuticals of the present invention exert an effect of increasing the frequency of bowel movement or the like, and are useful for the prevention or treatment of constipation. | 05-12-2016 |
| 20160145213 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE - The present invention relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT | 05-26-2016 |
| 20160151403 | SMALL MOLECULE MODULATORS OF P53 FAMILY SIGNALING | 06-02-2016 |
| 20160175302 | MASITINIB FOR TREATING GASTRIC CANCER | 06-23-2016 |
| 20160175331 | TREATMENT OF LEUKEMIA WITH ARTEMISININ DERIVATIVES AND COMBINATIONS WITH OTHER ANTINEOPLASTIC AGENTS | 06-23-2016 |
| 20160184262 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION - Compositions for treating autoimmune, allergic, or atopic disease comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, the compound that inhibits hyaluronan synthesis is 4-methylumbelliferone or a metabolite of 4-methylumbelliferone. Methods for treating autoimmune diabetes, multiple sclerosis and/or autoimmune demyelination, including administering to the subject a composition having a compound in an amount effective to inhibit hyaluronan synthesis in a mammalian subject, are also described. | 06-30-2016 |
| 20160184298 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) - A UGT2B inhibitor capable of increasing the bio-availability of a drug, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: capillarisin, isorhamnetin,β-naphthoflavone, α-naphthoflavone, hesperetin, terpineol, (+)-limonene, β-myrcene, swertiamarin, eriodictyol, cineole, apigenin, baicalin, ursolic acid, isovitexin, lauryl alcohol, puerarin, trans-cinnamaldehyde, 3-phenylpropyl acetate, isoliquritigenin, paeoniflorin, gallic acid, genistein, glycyrrhizin, protocatechuic acid, ethyl myristate, umbelliferone, PEG (Polyethylene glycol) 400, PEG 2000, PEG 4000, Tween 20, Tween 60, Tween 80, BRIJ® 58, BRIJ® 76, Pluronic® F68, Pluronic® F127, and a combination thereof. A UGT2B enhancer capable of enhancing a clearance rate of morphine-like analgesic agents, is a compound in a free base or a pharmaceutically acceptable salt form that is selected from the group consisting of: nordihydroguaiaretic acid, wogonin, trans-cinnamic acid, baicalein, quercetin, daidzein, oleanolic acid, homoorientin, hesperetin, narigin, neohesperidin, (+)-epicatechin, hesperidin, liquiritin, eriodictyol, formononetin, quercitrin, genkwanin, kaempferol, isoquercitrin, (+)-catechin, naringenin, daidzin, (−)-epicatechin, luteolin-7-glucoside, ergosterol, rutin, luteolin, ethyl myristate, apigenin, 3-phenylpropyl acetate, umbelliferone, glycyrrhizin, protocatechuic acid, poncirin, isovitexin, 6-gingerol, cineole, genistein, trans-cinnamaldehyde, and a combination thereof. | 06-30-2016 |
| 20160193240 | Ulmoside-A: Useful For Prevention Or Cure Of Metabolic Diseases | 07-07-2016 |
| 20160199399 | METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS | 07-14-2016 |
| 20160199430 | A Purified Extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma | 07-14-2016 |
| 20160374959 | TREATMENT OF EARLY STAGE PARKINSON'S DISEASE WITH A HYDROXYTYROSOL-CONTAINING POLYPHENOL FORMULATION - The invention provides a method for treating a subject suffering from early stage Parkinson's disease with a pharmaceutical formulation containing an olive polyphenol composition. The olive polyphenol composition includes hydroxytyrosol and at least one additional olive polyphenol, and the hydroxytyrosol represents about 40 wt. % to about 90 wt. % of the olive polyphenol composition. The formulation is administered to the subject within the context of a dosing regimen that provides a daily dosage of the olive polyphenol composition in the range of 30 mg to about 2500 mg. The invention additionally provides a method for reducing the dose of an antiparkinsonism drug used in the treatment of early stage Parkinson's disease, as well as a pharmaceutical formulation for treating early stage Parkinson's disease. | 12-29-2016 |
| 20220133764 | FLAVONOIDS AND ANIMAL HEALTH AND PERFORMANCE - The present invention relates to the use of naringin, its aglycone form naringenin or mixtures thereof in the modulation of the expression of some specific gene receptors in ruminants and/or pigs which positively impact on feeding behaviour, intake patterns and animal behaviour. | 05-05-2022 |
